CloneID: AIIB2
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was isolated by immunizing a Lewis rat with JAR choriocarcinoma cells.
Buffer Composition: PBS only.
Chimeric Use Statement: This chimeric human antibody was made using the variable domain sequences of the original Rat IgG1 format for improved compatibility with existing reagents assays and techniques.
Uniprot Accession No.: O14713
Specificity Statement: The antibody specifically binds β1 integrin extracellular domain.
Application Notes (Clone): The antibody immunoprecipitated the integrin subunits (Hall et al.,1990). This antibody was used for detection of β1 integrin expressed on CHO cells by flow cytometry (Takada et al., 1993; PMID: 7688727). The original format of the antibody or its F(ab′)2 fragments applied to single cells were capable of down-modulating β1 integrin signaling pathways (Wang et al., 1998; PMID: 9843973 and Weaver et al., 1997; PMID: 9105051). The antibody was used in immunofluorescence characterization of integrins in the HMT-3522 cells (Weaver et al., 1997; PMID: 9105051). The antibody inhibited tumor cell growth in several breast cancer cell lines (T4-2, MDA-MB-231, BT474, SKBR3, and MCF-7) and one nonmalignant cell line (S-1). Further, β1 integrin inhibition resulted in a significant loss of cancer cells, associated with a decrease in proliferation and increase in apoptosis, and a global change in the composition of residual colonies (Park et al., 2010; PMID: 16452209). The antibody was found to reduce the frequency of solid tumor stem cells. The antibody inhibited the growth of colon tumors and reduced the percentage of CD44+ cells. Tumors treated in mice showed a decrease when treated with the antibody. The humanized version of the antibody was constructed, showing potential for therapeutic uses (WO2009009114A3).
Deutsch
English
